Clinical Trials Directory

Trials / Completed

CompletedNCT03478124

Neuropsychological Evaluation for Early Diagnosis of PSP

The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy

Status
Completed
Phase
Study type
Observational
Enrollment
112 (actual)
Sponsor
Ospedale Generale Di Zona Moriggia-Pelascini · Academic / Other
Sex
Age
Healthy volunteers

Summary

The aim of this study is to better understand the nature of the cognitive decline in Progressive Supranuclear Palsy, the time of its development and the relation with the other cardinal features of the disease.

Detailed description

Progressive Supranuclear Palsy (PSP) is a neurodegenerative disease characterized by vertical supranuclear gaze palsy, early balance dysfunction and falls. Tau-protein aggregation, mainly in the brainstem, is the disease hallmark. Because of the similarities with Parkinson's disease (PD), the diagnosis is made approximately 4 years after the symptoms onset. Cognitive deficits are a leading feature of PSP and they actually represent one of the four functional core domains in the revised diagnostic criteria. The aim of this study is to better understand the nature of this cognitive decline, the time of its development and the relation with the other cardinal features of the disease.

Conditions

Interventions

TypeNameDescription
BEHAVIORALCognitive evaluationAn extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.

Timeline

Start date
2016-01-01
Primary completion
2018-03-01
Completion
2018-03-02
First posted
2018-03-27
Last updated
2018-03-27

Source: ClinicalTrials.gov record NCT03478124. Inclusion in this directory is not an endorsement.